Executive Change

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 8-K/A (Amendment No. 1)   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): May 24, 2021 ( April 14, 2021 )   ABEONA THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-15771   83-0221517 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1330 Avenue of the Americas , 33rd Floor , New York , NY 10019 (Address of principal executive offices) (Zip Code)   (646) 813-4701 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol   Name of each exchange on which registered Common Stock, $0.01 par value   ABEO   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On April 19, 2021, Abeona Therapeutics Inc. (the “Company”) filed a Current Report on Form 8-K disclosing under Item 5.02 that Leila Alland, M.D. and Donald Wuchterl were appointed to serve on the Board of Directors (the “Board”) of the Company effective on April 14, 2021. At the time of this filing, Dr. Alland and Mr. Wuchterl had not been appointed to serve on any committees of the Board.   Pursuant to Instruction (2) to Item 5.02 of Form 8-K, the Company is filing this amendment to its prior Current Report on Form 8-K for the sole purpose of disclosing that (i) Dr. Alland will serve as a member of the Board’s Compensation Committee and its Nominating and Corporate Governance Committee and (ii) Mr. Wuchterl will serve as a member of the Board’s Nominating and Corporate Governance Committee. The committee appointments became effective as of May 24, 2021.         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   May 28, 2021 Abeona Therapeutics Inc.   (Registrant)         By: /s/ Brendan M. O’Malley   Name: Brendan M. O’Malley   Title: Corporate Secretary